Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | HCRTR1 | O43613 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | HCRTR2 | O43614 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424773 | 1.00 | MAPT (1.00) | MAPTHTR2CMEN1KMT2AHTR2B | |
| SCHEMBL29424927 | 1.00 | MAPT (1.00) | MAPTHTR2CMEN1KMT2AHTR2B | |
| Hydrochloric Acid SCHEMBL226068 | 0.99 | HTR2C (1.00) | MAPTHTR2CMEN1KMT2AHTR2B | |
| Hydrochloric Acid SCHEMBL29440043 | 0.99 | HTR2C (1.00) | MAPTHTR2CMEN1KMT2AHTR2B | |
| SCHEMBL5816617 | 0.88 | MEN1 (0.79) | MAPTHTR2CMEN1KMT2AHTR2B | |
| SCHEMBL13916411 | 0.88 | MEN1 (0.79) | MAPTHTR2CMEN1KMT2AHTR2B | |
| Hydrochloric Acid SCHEMBL7655785 | 0.85 | HTR2C (0.98) | MAPTHTR2CMEN1KMT2AHTR2B | |
| SCHEMBL7098595 | 0.80 | HTR2C (0.77) | MAPTHTR2CMEN1KMT2AHTR2B | |
| Hydrochloric Acid SCHEMBL5964636 | 0.79 | HTR2C (0.76) | MAPTHTR2CMEN1KMT2AHTR2B | |
| Hydrochloric Acid SCHEMBL7660393 | 0.79 | HTR2C (0.76) | MAPTHTR2CMEN1KMT2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2696872-B1 | TREATMENT OF GLAUCOMA | UNIV INDIANA RES & TECH CORP (US) | 2019-01-16 | — | — | EP | claimed |
| US-8980910-B2 | Treatment of glaucoma | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-03-17 | — | — | US | claimed |
| US-20140039003-A1 | TREATMENT OF GLAUCOMA | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-02-06 | — | — | US | claimed |
| EP-1075478-B1 | PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-04-16 | — | — | EP | claimed |
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | UNIV DREXEL (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025023851-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |
| WO-2023172497-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING COCAINE USE DISORDER | DREXEL UNIVERSITY (US) | 2023-09-14 | — | — | WO | disclosed |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | Inserm (Institut National de la Santa et de la Recherche Medicale) (FR) | 2021-01-19 | — | — | US | disclosed |
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-05-23 | — | — | US | disclosed |
| US-20040138143-A1 | Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| US-20040127434-A1 | Novel adenosine analogues and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| US-20040097424-A1 | Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least one other active ingredient and the use of the product | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-20 | — | — | US | disclosed |
| US-20040077716-A1 | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| EP-1375508-A1 | N6-substituted adenosine analogues and their use as pharmaceutical agents | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030216370-A1 | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
| US-20030158094-A1 | Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-21 | — | — | US | disclosed |
| US-20030158119-A1 | Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | HCRTR1, HCRTR2, OXTR | MAPT 1815/4885HTR2C 1279/4885MEN1 2483/4885 |
| US-20030158094-A1 | Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product | ADRA1D, ADRA1B, ADRB3 | MAPT 3612/4885HTR2C 104/4885MEN1 1647/4885 |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | OXTR, OGFR, OXGR1 | MAPT 3749/4885HTR2C 560/4885MEN1 1980/4885 |
| US-20040127434-A1 | Novel adenosine analogues and their use as pharmaceutical agents | ADORA1, ADORA2A, ADORA2B | MAPT 4710/4885HTR2C 1758/4885MEN1 1814/4885 |
| US-20030216370-A1 | Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use | CPS1, AGPAT2, GLS | MAPT 4818/4885HTR2C 3616/4885MEN1 3096/4885 |
| US-20040077716-A1 | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use | DPP4, CPS1, GLS | MAPT 4816/4885HTR2C 3361/4885MEN1 3065/4885 |
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | CES2, CHAT, SLC18A2 | MAPT 237/4885HTR2C 31/4885MEN1 4731/4885 |
| US-20040138143-A1 | Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | SLC5A1, SLC5A2, UGGT1 | MAPT 4430/4885HTR2C 3152/4885MEN1 2983/4885 |
| US-20030158119-A1 | Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on | SULT1E1, BPNT1, CYP3A4 | MAPT 2517/4885HTR2C 146/4885MEN1 707/4885 |
| US-20140039003-A1 | TREATMENT OF GLAUCOMA | HCRTR2, HCRTR1, THOP1 | MAPT 1777/4885HTR2C 1091/4885MEN1 837/4885 |
| US-20040097424-A1 | Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least one other active ingredient and the use of the product | SULT1E1, CYP1A1, CYP2S1 | MAPT 3220/4885HTR2C 225/4885MEN1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.